A 25-year clinical history of portopulmonary hypertension associated with latent myeloproliferative disorder

Journal of Gastroenterology

Volumn 38, Issue 5, 2003, Pages 488-492

  Ito, Hideto ^a   Adachi, Yasushi ^a   Arimura, Yoshiaki ^a   Endo, Takao ^a   Hinoda, Yuji ^a   Imai, Kohzo ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Latent myeloproliferative disorder; Portal hypertension; Portal vein thrombosis; Portopulmonary hypertension; Splenomegaly

Indexed keywords

ANTICOAGULANT AGENT; BILIRUBIN; CILAZAPRIL; DIGOXIN; FUROSEMIDE; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; PROSTACYCLIN;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CASE REPORT; CELL INFILTRATION; CHRONIC LIVER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOSCOPY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOPOIETIC STEM CELL; HEPATIC VEIN; HUMAN; JAPAN; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG VASCULAR RESISTANCE; MYELOPROLIFERATIVE DISORDER; ONSET AGE; PHYSICAL EXAMINATION; PORTAL HYPERTENSION; PORTAL PHLEBOGRAPHY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK ASSESSMENT; SPLEEN BLOOD FLOW; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; VEIN THROMBOSIS;

CONSTRICTION, PATHOLOGIC; FATAL OUTCOME; FEMALE; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; MEGAKARYOCYTES; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PORTAL VEIN;

EID: 0038513478     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-002-1086-3     Document Type: Article

References (27)

1. Krowka MJ. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas. Hepatology 1997;25: 1282-4.
2. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-8.
3. Yang YY, Lin HC, Lee WC, Hou MC, Lee FY, Chang FY, et al. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. J Gastroenterol 2001;36:181-6.
4. Bayraktar Y, Tanaci N, Egesel T, Gokoz A, Balkanci F, Antiphospholipid syndrome presenting as portopulmonary hypertension. J Clin Gastroenterol 2001;32:359-61.
5. Wanless IR, Peterson P, Das A, Boitnott JK, Moore GW, Bernier V. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology 1990;12:1166-74.
6. Muller EW, De Wolf JT, Haagsma EB. Portal hypertension as presenting feature of a myeloproliferative disorder. Diagnosis and therapeutic dilemmas. Scand J Gastroenterol Suppl 1993; 200:74-9.
7. Shaldon S, Sherlock S. Portal hypertension in the myeloproleferative syndrome and the reticuloses. Am J Med 1962;32:758-64.
8. Rosenbaum DL, Murphy GW, Swisher SN. Hemodynamic studies of the portal circulation in myeloid metaplasia. Am J Med 1966;41:360-8.
9. Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988;94:1063-9.
10. Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 1991;63:101-6.
11. Barosi G, Buratti A, Costa A, Liberato LN, Balduini C, Cazzola M, et al. An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer 1991;68:2310-8.
12. Cardin F, Graffeo M, McCormick PA, McIntyre N, Burroughs A. Adult "idiopathic" extrahepatic venous thrombosis. Importance of putative "latent" myeloproliferative disorders and comparison with cases with known etiology. Dig Dis Sci 1992;37:335-9.
13. Raffy O, Sleiman C, Vachiery F, Mal H, Roue C, Hadengue A, et al. Refractory hypoxemia during liver cirrhosis. Hepatopulmonary syndrome or "primary" pulmonary hypertension? Am J Respir Crit Care Med 1996;153:1169-71.
14. Reisner SA, Rinkevich D, Markiewicz W, Tatarsky I, Brenner B. Cardiac involvement in patients with myeloproliferative disorders. Am J Med 1992;93:498-504.
15. Garcia-Manero G, Schuster SJ, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol 1999;60:130-5.
16. Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 1986;23:177-82.
17. Silverstein MN, Wollaeger EE, Baggenstoss AH. Gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia. Arch Intern Med 1973;131:532-7.
18. Dal Palu C, Ruol A, Belloni G. Postsinusoidal portal hypertension in a patient with chronic lymphatic leukemia: report of a case. Am J Dig Dis 1963;8:845-51.
19. Tsao MS. Hepatic sinusoidal fibrosis in agnogenic myeloid metaplasia. Am J Clin Pathol 1989;91:302-5.
20. Broe PJ, Conley CL, Cameron JL. Thrombosis of the portal vein following splenectomy for myeloid metaplasia. Surg Gynecol Obstet 1981;152:488-92.
21. Valla D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985;103:329-34.
22. Jones FD, Kuo PC, Johnson LB, Njoku MJ, Dixon-Ferguson MK, Plotkin JS. The coexistence of portopulmonary hypertension and hepatopulmonary syndrome. Anesthesiology 1999;90:626-9.
23. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000;95: 2226-33.
24. Takasaki M, Takahashi I, Takamatsu M, Yorimitsu S, Yorimitsu Y, Takeda I, et al. Endoscopic injection sclerotherapy for esophageal variceal hemorrhage in a patient with idiopathic myelofibrosis. J Gastroenterol 1996;31:260-2.
25. Matsumoto M, Matsumoto H, Miyake T, Nakao K, Iwata K, Yoshida N, et al. Endoscopic injection sclerotherapy for esophageal variceal hemorrhage in myeloproliferative disorder: case report. J Gastroenterol 1995;30:244-7.
26. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997;63:604-6.
27. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-8.